Current SPs are irrelevant. Share structure, market cap, biopharma sector, debt financing, convertible structures, and potential market all factor into share price.
Ehrlich's current company, which he rescued from near bankruptcy, has a flag drug against cancer in Phase 1. Cancer drugs, as you know, are regarded as highly costly to bring to market, even though the potential market is in the billions of dollars. It has $5 million in the bank with debt financing available up to $20 million. Two other drugs are starting or just started Phase 2b and Phase 1 bridge studies, with a 4th drug entering trials. The full dilution is ~150 million shares which puts the current cap at ~$240 million in spite of the likelihood of more debt financing.
So, NNVC has ~28 million in the bank (enough for Phase1 through start of Phase 3 for 2 versions of nanoviricides) with 50 million shares fully diluted. You do the math, but I get a lot higher than $3, by about $10.
News 
Market Data 
Discover 
AI
